Gupta E - Search Results

1

Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies.

DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, Patel J, Goodin S, Medina M, Medina P, Zamek R, Zhang C, White E, Gupta E, Hait WN. DiPaola RS, et al. Among authors: gupta e. J Clin Oncol. 1999 Jul;17(7):2213-8. doi: 10.1200/JCO.1999.17.7.2213. J Clin Oncol. 1999. PMID: 10561278 Clinical Trial.

2

In vitro activation of irinotecan to SN-38 by human liver and intestine.

Ahmed F, Vyas V, Cornfield A, Goodin S, Ravikumar TS, Rubin EH, Gupta E. Ahmed F, et al. Among authors: gupta e. Anticancer Res. 1999 May-Jun;19(3A):2067-71. Anticancer Res. 1999. PMID: 10470149

3

Pharmacokinetics of orally administered camptothecins.

Gupta E, Vyas V, Ahmed F, Sinko P, Cook T, Rubin E. Gupta E, et al. Ann N Y Acad Sci. 2000;922:195-204. doi: 10.1111/j.1749-6632.2000.tb07038.x. Ann N Y Acad Sci. 2000. PMID: 11193895

4

High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin.

Ahmed F, Vyas V, Saleem A, Li XG, Zamek R, Cornfield A, Haluska P, Ibrahim N, Rubin EH, Gupta E. Ahmed F, et al. Among authors: gupta e. J Chromatogr B Biomed Sci Appl. 1998 Apr 10;707(1-2):227-33. doi: 10.1016/s0378-4347(97)00615-4. J Chromatogr B Biomed Sci Appl. 1998. PMID: 9613954 Clinical Trial.

5

The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s).

Gupta E, Luo F, Lallo A, Ramanathan S, Vyas V, Rubin E, Sinko P. Gupta E, et al. Anticancer Res. 2000 Mar-Apr;20(2A):1013-6. Anticancer Res. 2000. PMID: 10810389

6

Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.

Saleem A, Ibrahim N, Patel M, Li XG, Gupta E, Mendoza J, Pantazis P, Rubin EH. Saleem A, et al. Among authors: gupta e. Cancer Res. 1997 Nov 15;57(22):5100-6. Cancer Res. 1997. PMID: 9371509

7

Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.

Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson J Jr, Schwartz G, Patnaik A, Smith L, Molpus K, Felton S, Gupta E, Ferrante KJ, Tortora A, Sonnichsen DS, Skillings J, Rowinsky EK. Hidalgo M, et al. Among authors: gupta e. J Clin Oncol. 2001 May 1;19(9):2493-503. doi: 10.1200/JCO.2001.19.9.2493. J Clin Oncol. 2001. PMID: 11331328 Clinical Trial.

8

Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.

Plummer R, Ghielmini M, Calvert P, Voi M, Renard J, Gallant G, Gupta E, Calvert H, Sessa C. Plummer R, et al. Among authors: gupta e. Clin Cancer Res. 2002 Sep;8(9):2788-97. Clin Cancer Res. 2002. PMID: 12231518 Clinical Trial.

9

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ. Gupta E, et al. J Clin Oncol. 1997 Apr;15(4):1502-10. doi: 10.1200/JCO.1997.15.4.1502. J Clin Oncol. 1997. PMID: 9193346

10

A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer.

Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H. Rizvi NA, et al. Among authors: gupta e. Clin Cancer Res. 2004 Mar 15;10(6):1963-70. doi: 10.1158/1078-0432.ccr-1183-02. Clin Cancer Res. 2004. PMID: 15041713 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

446 results

Search Page

Filters